Brief: Sonnet BioTherapeutics Successfully Completes First Safety Review Of SON-1010 In Combination With Trabectedin In Certain Sarcomas
26/03/2025 13:11
March 26 (Reuters) - Sonnet Biotherapeutics Holdings Inc SONN.O: SONNET BIOTHERAPEUTICS SUCCESSFULLY COMPLETES FIRST SAFETY REVIEW OF SON-1010 IN COMBINATION WITH TRABECTEDIN IN CERTAIN SARCOMAS SONNET BIOTHERAPEUTICS HOLDINGS : SAFETY REVIEW COMMITTEE FOUND NO UNEXPECTED TOXICITIES IN EARLY DOSING OF SON-1010 IN FIRST 7 PATIENTS AT MTD SONNET BIOTHERAPEUTICS : ANNUAL REVIEW SHOWED EXTENDED SAFETY OF SON-1010 MONOTHERAPY AT MTD WITH CLINICAL BENEFIT IN 83% OF PATIENTS AT THAT DOSE Source text: ID:nGNX89JD06 Further company coverage: SONN.O ((Reuters.Briefs@thomsonreuters.com;))